---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-018743"
form_type: "8-K"
ticker: "MLAB"
cik: "0000724004"
company_name: "MESA LABORATORIES INC /CO/"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:36:51.331263+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mesa Labs Q1: revenue up 44% but net loss of $1.4M; organic growth slows to 3%

## Summary
- GAAP diluted EPS loss of ($0.27) vs prior-year EPS of $0.38; net loss of ($1.438M) from $1.995M income.
- Revenue $50.5M (+44% total, +3% organic); non-GAAP adjusted OI $6.158M (-33%) or $1.17/share.
- Clinical Genomics (29% rev) hit by China lockdowns; Sterilization & Disinfection down 2%.
- Biopharma Development grew 24%; Calibration Solutions fell 6% on supply chain shortages.
- Unusual items: $356K in Agena integration costs; management cites FX, labor, and material headwinds.

## SEC filing metadata
- accession: 0001437749-22-018743
- form_type: 8-K
- ticker: MLAB
- cik: 0000724004
- company_name: MESA LABORATORIES INC /CO/
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724004/000143774922018743/0001437749-22-018743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724004/000143774922018743/mlab20220803_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-018743
- JSON: https://secwatch.observer/filing/0001437749-22-018743.json
- Plain text: https://secwatch.observer/filing/0001437749-22-018743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.